| Name | Title | Contact Details |
|---|
At OPTIMUM, an architecture, furniture, and technology (A/F/T) products collective, were not defined by size or the number of product lines but by our unique design-thinking approach. We believe in solving workplace challenges by optimizing the integration of architecture, furniture, and technology to create seamless experiences for those who design, plan, deliver, and occupy spaces. What sets us apart is our focus on offering aesthetically appealing, high-performance products that balance design and cost-efficiency, along with our partnerships with flexible manufacturers who can customize solutions to meet specific needs. Success isnt about individual pieces; its about the synergy that happens when people, elements, and solutions come together, resulting in outcomes far greater than the sum of their parts. This philosophy drives everything we do at OPTIMUM as we enhance the environments where we live, work, learn, and heal.
The RAMPF Group stands for engineering and chemical solutions and caters to the economic and ecological needs of industry. Our range of competences includes: 🧪 Production and recycling of materials for modeling, lightweight construction, bonding, and protection ⚙️ Technical production systems for precise, dynamic positioning and automation, as well as technologies for complex composite parts production 💡 Comprehensive range of solutions and services, particularly for innovative customer-specific requirements Please find our imprint here: https://www.rampf-group.com/de/impressum/ https://www.rampf-group.com/en/imprint/
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Grassi was founded in 1980 by Louis C. Grassi, with only an empty filing cabinet and a desk. Since then, Grassi has grown to become one of the nations largest accounting firms with more than 360 employees and nine office locations in the U.S. and Italy. Our team of experienced CPAs, CFOs, business consultants, forensic accountants, valuation experts, trust and estate specialists and tax advisors offer strategic advice and customized solutions to overcome all obstacles standing in the way of your greatest success. We do this through our commitment to add Strength in Certainty to every business decision and financial move you make.